1 results match your criteria: "Virginia Commonwealth University. Richmond VA (United States). emsisson@vcu.edu.[Affiliation]"
Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series.
Pharm Pract (Granada)
December 2019
PharmD. Department of Pharmacotherapy & Outcomes Science, School of Pharmacy, Virginia Commonwealth University. Richmond VA (United States).
Background: National treatment guidelines recommend glucagon-like peptide receptor agonists (GLP-1 RAs) as add-on therapy to oral agents. However, GLP-1 RAs in combination with dipeptidyl peptidase-4 (DPP-4) inhibitors is not recommended due to a lack of evidence.
Objective: This case series aims to describe the efficacy and safety of once-weekly GLP-1 RAs administered concomitantly with DPP-4 inhibitors in patients with type 2 diabetes.